Manolis is Deputy Director, Value and Access at IFPMA. His work focuses on procurement, pricing, market access, health technology assessments as well as on coordinating industry engagement on these topics with multilateral stakeholders such as WHO and OECD.
He has 26 years of experience, both in pharma and medical devices. He previously worked at Boehringer Ingelheim, Novo Nordisk, and Medtronic in market access and government affairs roles in multiple therapies and geographies, as well as on trade negotiations. Until recently, he was elected Chair of the Research and Innovation Committee of MedTech Europe, with focus on EU funded projects.
Manolis holds a master’s degree in health studies from the University of Kent in Canterbury, UK. and a B.Sc. in Economics from the National and Kapodistrian University of Athens, Greece. He has also acquired certificates on “The Economic Evaluation of Medical Therapies and Other Health Care Technologies” from the London School of Economics and on “Executive Leadership Skills” from the Wharton University in Philadelphia, USA.
More from Firstname Surname
Getting procurement right: sustainable and secure supply chains that support access to medicines
During the OECD Global Public Procurement Forum, leaders will discuss how public procurement can be used to unlock social, environmental and economic benefits. Sustainable procurement can be an opportunity for collaboration between healthcare systems and industry to get this balance right. However, for this approach to be successful, it must be carefully implemented. Without a thoughtful design, procurement policies can inadvertently introduce requirements that disrupt supply chains, limit product availability, and put the brakes on future innovation. In this blog, IFPMA shares a set of core principles that can guide policy design on sustainable procurement.
Read more
Adaptive HTA: striking the right balance between rapid assessments and local health impact
What is an HTA and how is it used? Health technology assessment (HTA) is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision-making in order to promote an equitable, efficient, and high-quality health system. An HTA agency...
Read more
Together, Taking on Drug Resistant Malaria
The human cost of malaria affects countless families worldwide – including my own. As a young man, my grandfather suffered with the disease whilst serving with British troops in India. He described it as having ‘stolen a year of his life’, but that his long illness paled in comparison to the suffering of the local...
Read more